Goldman Sachs Starts Teva Pharma (TEVA ) at Buy

Goldman Sachs analyst Matt Dellatorre initiates coverage on Teva Pharma (NYSE: TEVA ) with a Buy rating and a price target of $24.00.

The analyst comments: "Overall, we see an improving core business, with upside to near-mid-term consensus EBITDA estimates driven by strong growth in the branded segment. On the generics side, we expect limited (in-line with consensus) growth over the next few years, as an expanding biosimilars portfolio (5 additional US launches FY25-FY27) and other new product launches are off-set by the gRevlimid settlement expiration in 2026. On the branded side, we expect robust (~10% above consensus in FY27) growth on continued momentum for key assets (Austedo, Uzedy, Ajovy, and LAI olanzapine) based on our KOL diligence, the latest script data, and recent commercial investment and execution (e.g., direct-to-consumer (DTC) campaign and access), acknowledging the industry-wide Part D re-design hit to 2025 growth and margins. Restructuring and cost-cutting efforts represent upside to our FY26+ EBITDA estimates, while potential tariffs (which we continue to monitor) represent downside. Overall, we are ~6% above FactSet consensus EBITDA estimates in 2027 and see the potential for this to expand further on continued execution."

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $17.25 yesterday.

You May Also Be Interested In

• Seaport Global Securities Starts ADI Global Distribution (ADIG) at Buy
• Belite Bio (BLTE) Reiterated at Buy by Benchmark on Tinlarebant NDA Acceptance by FDA
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recover